Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
about
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceAnti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPABiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesEarly short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatmentPharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPAPhase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production.Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical courseAntiretroviral tissue kinetics: in vivo imaging using positron emission tomography.Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 InfectionProdrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
P2860
Q27692040-0AF10225-39C3-406F-81CC-D0AF90755A8DQ28379404-F14B1208-7AB6-405E-94D2-E401DC83BB3AQ28775900-8250E8E6-54CB-4D07-B106-1C54B2E1571DQ33643898-F96D3D3F-79E3-41E9-9DFB-646C26BD0C7FQ33769993-B407FF14-90FD-40D5-AE84-33C837A90149Q33797464-1356104B-BA19-4A21-B50B-4F67F8A97DA0Q33799700-124070EE-723B-4E0A-BCA0-AC7E6FD15160Q33805141-D225C327-25F1-4A1D-9E29-1AD9C1DFF908Q33883722-9913A712-FA66-49C1-AFA5-48DCEB5771B0Q33938112-F7CA85BA-666F-4723-AC35-BC81EC38FFC5Q33976617-B7A009DA-9FDA-4FFF-A39A-525D62A25601Q33983070-3A9779B5-2102-4BCA-9E7A-4DB90BD31F6CQ33983556-97A90F5B-A9D5-46AB-94AF-7458153D41FAQ34544211-8B4407D3-6ED5-42CA-AE58-680D6C7F9E56Q34707606-00BB0F3A-05E4-4DB5-9287-6E5900FA269FQ35155913-C6C8F4BF-A3DF-48DB-B9C8-08A7127D10FFQ35558801-180DCA24-6100-423A-9ECC-EA99544920AAQ35752812-DA6A861F-1CB7-42A1-B8FB-9E8896EE3FD4Q35823231-6192ED7D-DCA4-4597-8252-0D9162333297Q35939695-1101F653-D712-438E-B942-38C8BB91CFCAQ36172455-FB9F3BBC-9EF8-44EC-A6AD-81B6B03CC129Q36188725-C7FDC544-4239-4C68-81B3-9DA3CF878BB7Q36243626-F01310F5-DDB8-44BE-BD0F-B3CA36651EC8Q36601857-9FEBA6A0-B83C-4585-9971-B84CDEC3A320Q36706781-7F9A77D3-E4E0-40E4-903D-28D5740D80CFQ36870864-4DBA46B5-8E23-4EF4-81CE-E877E8CD6BF4Q37209876-E5DC7D8A-1A3F-4378-AF8E-8A774522A1ADQ37392720-5A2CD64D-8975-4812-9F7F-932C55A711F5Q37421891-099CB1A4-CDD6-4BBA-B794-C38FA2692CEBQ37705969-4D7F03A5-6039-46BA-8B9C-1E7ABB93F98DQ37780687-3E408DA2-F382-443F-B32F-501EF5451F1EQ38833637-4BB83890-F86B-4139-9B12-E543F8875FD6Q39651462-DD57E0B9-855B-4C8E-8B9C-BC2B1CAC55DA
P2860
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Safety, pharmacokinetics, and ...... erapy, in HIV-infected adults.
@ast
Safety, pharmacokinetics, and ...... erapy, in HIV-infected adults.
@en
type
label
Safety, pharmacokinetics, and ...... erapy, in HIV-infected adults.
@ast
Safety, pharmacokinetics, and ...... erapy, in HIV-infected adults.
@en
prefLabel
Safety, pharmacokinetics, and ...... erapy, in HIV-infected adults.
@ast
Safety, pharmacokinetics, and ...... erapy, in HIV-infected adults.
@en
P2093
P2860
P356
P1476
Safety, pharmacokinetics, and ...... herapy, in HIV-infected adults
@en
P2093
J F Rooney
N S Hellmann
P Barditch-Crovo
P S Lietman
P2860
P304
P356
10.1128/AAC.42.9.2380
P407
P577
1998-09-01T00:00:00Z